The first thing I ask a pharma or biotech team about their podcast is not the guest list or the cameras, right, it is who signs off, because in this industry the edit is only half the job and the other half is getting a clean, traceable file through review without three people working from three different versions. In the US, a drug company's promotional material commonly passes through medical, legal and regulatory review before it is released, and a branded podcast sits inside that same rule of thumb, which means the editor is part of a review process whether they planned for it or not. Pixel Samy Podcast was set up for exactly this kind of careful work, it is my podcast video editing team in Dubai, and no cut on a medical affairs or R&D conversation is made until a person on that team has listened to the guest from the first word to the last, and the Studio plan, at 299 dollars per episode running up to sixty minutes, includes unlimited free revisions, which matters a great deal when reviewers will ask for changes more than once.
Why is editing a pharma or biotech podcast different from editing any other company show?
Editing a pharma or biotech podcast is different because the episode will usually pass through medical, legal and regulatory review before anyone outside the company hears it, so the editor's job is not only to make the conversation clear and watchable, it is to produce versions reviewers can track, change nothing that alters a claim, and keep the final approved file identical to what gets published.
In most company podcasts, right, a loose phrase gets a shrug. In life sciences, a sentence that drifts from what the data supports, or a cut that drops a qualifier, becomes a problem for the reviewer and for you. So the editing decisions, right, are more conservative by design. We still tighten, we still cut the rambling and the false starts, but we do it in a way that leaves the meaning of every scientific statement exactly where the speaker put it.
I would add that this is general experience from the editing side, not regulatory advice. Your own reviewers and your own policies decide what can be said, and our role is to make their work faster, never to second-guess it.
How does a podcast edit fit into medical, legal and regulatory review?
A podcast edit fits into medical, legal and regulatory review by treating each cut as a numbered review version: the editor delivers a first cut, reviewers comment against timecodes, the editor applies only those changes and returns the next numbered version, and the loop repeats until the version is approved, at which point that exact file is exported for publishing and nothing is touched afterwards.
The phrase I use internally is editing around the review step instead of against it, right, which basically means we plan the edit for review from the start. That is one, a transcript with timecodes travels with each version so a reviewer can comment on text rather than scrubbing through video. Secondly, every on-screen word, lower thirds, titles, references, is listed so it can be checked separately from the speech. And on the review copy itself we can burn in the version number and timecode so no comment ever lands on the wrong file.
The first cut reaches you within 48 hours of upload, and each round of notes is turned around a working day later, so the review timeline is mostly about how long your reviewers need, not about us.
How do you keep version control straight across several rounds of review?
We keep version control straight across several rounds of review by naming every export with the episode, the version number and the date, keeping each superseded version in the shared folder rather than overwriting it, logging which comments were applied in each round, and exporting the published files only from the version your reviewers approved, so the history of every change can be shown later if anyone asks.
The worst thing that can happen in a regulated edit is someone publishing version four when version six was approved, and without a naming system it is a very easy mistake to make on a busy Friday. A finance show has almost exactly the same problem with a different regulator, and how approval versions work for finance podcasts explains why the approved file and the published file must be the same file.
We also keep the project files organised so the record survives us. You own them, so if your company ever changes editor, your next team can open the project and see what was cut and when.
How do you edit scientific guests without changing what they said?
We edit scientific guests without changing what they said by cutting only between complete thoughts, never joining two fragments into a new sentence, keeping every qualifier and caveat attached to the claim it belongs to, and checking names of molecules, trials, endpoints and institutions against a spelling list from your team, so the guest sounds clearer without saying anything they did not say.
Scientists are often careful speakers, right, they hedge, they correct themselves, they add a condition halfway through a sentence, and a careless editor removes exactly the words that make the statement accurate. Our editors are told to leave those words in. Where a guest misspeaks a number or a name, we do not fix it ourselves with a clever cut, we flag the timecode for your medical reviewer to decide.
Getting the science readable on screen is its own craft, and science podcast editing for researchers and science communication shows goes into graphics and on-screen terms. If your team works out of Raleigh or Durham, how Raleigh and Durham biotech shows handle the review step covers the same territory from a city angle.
In a regulated show, the safest edit is the one where every reviewer is looking at the same version.
What should never disappear from a pharma podcast without reviewers seeing it?
Nothing your reviewers asked to be included should ever disappear from a pharma podcast without them seeing the change, which means disclosures, balancing statements, references, speaker affiliations and any wording added at review are treated as locked, carried into every version and every clip, and only moved or shortened when a reviewer has approved that exact change.
This is where editing against the review step goes wrong, right, and it usually goes wrong quietly. An editor trying to make a clip punchier trims the line that a reviewer required, or a lower third with a guest's affiliation is dropped because it looked cluttered, and suddenly a file that was approved is no longer the file being published. Clips deserve their own care, because a thirty second vertical cut can take a sentence out of the context that made it acceptable, so clips should go through review as their own items.
Can confidential or unpublished data safely reach a podcast editor?
Confidential or unpublished data can reach a podcast editor only if your company decides it should, and the safer default for a life sciences show is to keep unpublished results, pipeline details and anything patient-identifiable out of the recording altogether, because the simplest way to protect sensitive material in an edit is for it never to be in the raw files in the first place.
If something sensitive slips into a recording, a guest mentions a trial site or an unannounced partner, we flag it with a timecode for your team rather than deciding on our own, and questions about how files are stored and who can open them are worth raising on the first call. The full set of questions to ask is worked through in editing podcast recordings that contain confidential material. Where patients or clinicians appear, the privacy and consent questions overlap heavily with those faced by hospitals and health systems running their own podcasts.
Let me be direct with you for a second: if your reviewers currently receive podcast files by email with names like final_v2_new, the fix is not a better editor, it is a better system, and you can ask for that system from whoever you hire.
When should a life sciences company keep podcast editing in house?
A life sciences company should keep podcast editing in house when its policies do not allow recordings to leave company systems, when an internal video team already has the capacity and knows the review process, or when episodes routinely contain unpublished data, because in those situations an external editor adds risk and coordination without adding enough value to justify it.
There is also a case, right, for a large production company if you are making a single high budget documentary series with location filming, actors or animation. Where an outside team like ours makes sense is the regular show, monthly or fortnightly, recorded on two or three cameras, where your team needs consistent edits, traceable versions and a predictable turnaround so the review calendar can be planned in advance.
What does pharma podcast editing cost with several review rounds?
Pharma podcast editing with several review rounds usually sits on the Studio plan at 299 dollars per episode for up to sixty minutes, because Studio includes unlimited free revisions alongside two to four synced cameras, 4K delivery and custom graphics, so three or four rounds of review comments do not change the price of the episode.
The Starter plan includes a single free revision, which suits simpler shows but rarely suits a regulated one. Captions and transcript files are scoped on the call, and your captions should spell every drug and trial name correctly, which matters because YouTube lets you upload your own caption files instead of relying on automatic ones. All options are on the Starter and Studio pricing, and nothing is billed on retainer.
Where a life sciences team should start
The best first step is a 15 minute call with me, bring a recent episode or a pilot that is waiting for review, and I will walk you through how I would version it, what I would change in the edit and what it would cost, or email samy@pixelsamy.com if your calendar is full of review meetings. The upload, cut and revision sequence is shown in how the editing process works. Pixel Samy Podcast works well for the communications or medical affairs team that already has good science to talk about and a review process it trusts, because in this industry the best edit is not the cleverest one, it is the one that reaches the public exactly as your reviewers approved it.
So yeah. That's my way of saying it.